Search clinical trials for: antimuscarinic agent

Total 188913 results

Washington University School of Medicine
American Academy of Clinical Toxicology

Not yet recruiting

Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium (RIVA-AP)

Anticholinergic Toxicity

United States
Washington University School of Medicine
American Academy of Clinical Toxicology

Not yet recruiting

Rivastigmine for Antimuscarinic Delirium (RIVA-AM)

Anticholinergic Toxicity

United States
National Taiwan University Hospital

Not yet recruiting

Association With Low Compliance Bladder in Women With LUTS

Urinary Bladder, Overactive | Urinary Incontinence | Pelvic Organ Prolapse | Urinary Bladder Neck Obstruction

Taiwan
Pamukkale University

Not yet recruiting

Transcutaneous Tibial Nerve Stimulation in Antimuscarinic Naive and Refractory Women With Idiopathic Overactive Bladder

Urinary Bladder, Overactive

Turkey
University of Colorado, Denver
American Academy of Clinical Toxicology

Completed

Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome (TAAT)

Anticholinergics Toxicity

United States
Astellas Pharma Singapore Pte. Ltd.

Completed

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Overactive Bladder (OAB)

Korea, Republic of, Australia
Novartis Pharmaceuticals

Completed

A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease

Germany, Poland, Romania, Hungary, Sweden, Russian Federation, Bulgaria, Finland, Israel, Belgium
Stéphane Bolduc
Pfizer

Completed

Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children. (FOXY2015)

Overactive Bladder

Canada
University of Alabama at Birmingham
Allergan

Completed

Bladder Antimuscarinic Medication and Accidental Bowel Leakage (BAMA)

Fecal Incontinence | Urinary Incontinence, Urge

United States
Astellas Scientific & Medical Affairs, Inc.

Completed

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) (PERSPECTIVE)

Urologic Diseases | Overactive Bladder | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Canada
Hai Yen Eye Care
Brien Holden Vision

Completed

Effects of Low Concentration Atropine on Pupillary Size and Accommodative Amplitude

Myopia

Vietnam
Ankara Training and Research Hospital
Ministry of Health, Turkey

Completed

Behavioural Therapy With Checklist for Overactive Bladder

Overactive Bladder

Turkey
CHU de Quebec-Universite Laval

Completed

Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder (Mirabegron)

Overactive Bladder | Urinary Incontinence
CHU de Quebec-Universite Laval

Completed

Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder (Add-on-Mira)

Overactive Bladder | Urinary Incontinence
Samsung Medical Center

Completed

Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.

Overactive Bladder

Korea, Republic of
The Cleveland Clinic
Pfizer

Unknown

Premarin Versus Toviaz for Treatment of Overactive Bladder

Overactive Bladder

United States
Stanford University
Allergan

Completed

Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease

Urinary Incontinence | Parkinson's Disease | Neurogenic Bladder | Clostridium Botulinum Toxin Adverse Reaction

United States
Buddhist Tzu Chi General Hospital

Completed

Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome

Overactive Bladder

Taiwan
AstraZeneca

Completed

Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Germany
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Czech Republic, Germany, Hungary, Poland
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics (VEST)

Urinary Bladder, Overactive

Czech Republic
Jeil Pharmaceutical Co., Ltd.

Completed

Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin

Overactive Bladder | Benign Prostatic Hyperplasia | LUTS

Korea, Republic of
Jeil Pharmaceutical Co., Ltd.

Completed

Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers

Overactive Bladder | Benign Prostatic Hyperplasia | LUTS
Jeil Pharmaceutical Co., Ltd.

Completed

The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers.

Overactive Bladder | Benign Prostatic Hyperplasia | LUTS(Lower Urinary Tract Symptoms)
Swiss Paraplegic Centre Nottwil

Completed

Effects of Antimuscarinics on Cognition in Spinal Cord Injury

Mild Cognitive Impairment | Spinal Cord Injuries

Switzerland
National Taiwan University Hospital

Unknown

Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients

Overactive Bladder Syndrome

Taiwan
Novartis Pharmaceuticals

Completed

NVA237 BID Versus Placebo Twelve-week Efficacy Study

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Completed

NVA237 Versus Placebo 12-week Efficacy Study

Chronic Obstructive Pulmonary Disease

United States
Pierre Fabre Medicament

Completed

Bronchodilator Properties and Safety in Asthma

Asthma

Germany
Buddhist Tzu Chi General Hospital

Completed

Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1

Bladder Outlet Obstruction

Taiwan
US Department of Veterans Affairs

Completed

Behavioral Treatment of Overactive Bladder in Men (MOTIVE)

Overactive Bladder

United States
National Taiwan University Hospital

Completed

Studies of Psychiatric Predisposing Factors, Treatment-related Cardiovascular Effects, and Prognostic Factors Associated With Antimuscarinic Drug (Tolterodine) for Female Overactive Bladder Syndrome

Antimuscarinic Drug

Taiwan
Samsung Medical Center
Pfizer

Completed

Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder

Overactive Bladder

Korea, Republic of
Astellas Pharma Europe Ltd.

Completed

Vesitirim™ in Men Postmarketing Observational Study (VIM)

Overactive Bladder (OAB) | Lower Urinary Tract Symptoms (LUTS)

Ireland
National Taiwan University Hospital

Unknown

Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug

Overactive Bladder Syndrome

Taiwan
Astellas Pharma Inc

Completed

A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability (SENIOR)

Cognition

United Kingdom
Novartis

Completed

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States, Spain, Turkey, France, Netherlands, Germany
APOGEPHA Arzneimittel GmbH

Completed

Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity

Urologic Diseases | Urinary Incontinence | Urinary Bladder, Neurogenic | Neurogenic Urinary Bladder Disorder | Bladder Disorder, Neurogenic | Urinary Bladder Disorder, Neurogenic | Neurogenic Bladder Disorder | Urinary Bladder Neurogenic Dysfunction | Overactive Detrusor Function

Romania, Austria, Germany
Pfizer

Completed

A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder. (SOFIA)

Urinary Bladder, Overactive

Portugal, Spain, Turkey, Finland, Germany, Norway, Sweden, Slovakia, Italy, Austria, United Kingdom, Belgium, Denmark, Israel, Switzerland
Samsung Medical Center

Completed

Efficacy and Safety of Selective Serotonin Reuptake Inhibitor (SSRI) in Overactive Bladder Patients

Overactive Bladder

Korea, Republic of
University of Saskatchewan
Royal University Hospital Foundation

Completed

Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness

Asthma

Canada
Università degli Studi dell'Insubria

Completed

Topical Oestrogens and Antimuscarinics In The Treatment Of Detrusor Overactivity

Overactive Bladder

Italy
APOGEPHA Arzneimittel GmbH

Completed

Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence

Overactive Bladder | Urinary Incontinence | Children
Novartis

Completed

A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.

Overactive Bladder Syndrome

United States
Novartis

Completed

A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder

Overactive Bladder Syndrome

United States
Novartis
Procter and Gamble

Completed

Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder

Overactive Bladder (OAB)

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Not yet recruiting

M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis

Radiation Dermatitis

United States
University of Illinois at Chicago

Not yet recruiting

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer (BRE-10)

Breast Cancer | HER2-positive Breast Cancer
Medical University of South Carolina
National Institute on Drug Abuse (NIDA)

Not yet recruiting

ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain (ACTION)

Chronic Pain | Opioid Withdrawal

United States
Taizhou Hospital

Not yet recruiting

Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell (SCLC)

SCLC | Maintenance Treatment

Search clinical trials for: antimuscarinic agent

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations